Vikrant Shrotriya, Corporate Vice President & Managing Director of Novo Nordisk India, during a session at India Today Conclave 2025, said that many celebrities may not want to admit to taking ...

As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...

R esearch funded by Novo Nordisk and published in The New England Journal of Medicine in 2024, found people with knee osteoarthritis who were treated with semaglutide for 68 weeks had ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

and Novo Nordisk revealed new data pointing to a “clinically meaningful” improvement in osteoarthritis patients’ pain and physical function in the STEP 9 trial.

In November 2023, PBAC reviewed Novo Nordisk’s submission ... related conditions needed to be obstructive sleep apnoea, osteoarthritis of the knee, or pre-diabetes. However, PBAC concluded ...

People with a high body weight living in England can now access subsidised weight-loss drugs to treat their obesity.

The US regulator is carrying out a standard 10-month review of tanezumab as a treatment for chronic pain due to moderate-to-severe osteoarthritis (OA) in those who can’t get sufficient pain ...